History of Esbriet (pirfenidone)

History of Esbriet (pirfenidone)

While the therapy was approved for use in 2014 in the US, Japan was the first country to approve its commercial use in 2008, followed by India in 2010, Europe in 2011, and China in 2013. Because IPF is considered a rare condition, this drug was…

What It’s Like To Live With IPF?

“Watch the video shared by the Canadian Pulmonary Fibrosis Foundation to understand what is like to live with IPF through the eyes of patients and their families.” Learn more about Esbriet that addresses Idiopathic Pulmonary Fibrosis: http://bit.ly/Esbriet…

IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015

The American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, included a breakfast symposium where a panel of experts shared practical tips to help clinicians assess, diagnose, and manage idiopathic pulmonary fibrosis (IPF) and co-morbidities linked to the disease. Dr. Timothy Whelan, associate professor…

OFEV® (Nintedanib) Efficacy Supported in New Study

Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015). The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both the efficacy and safety…

LARIAT Trial Shows Benefits of Reata’s Bardoxolone Methyl in Treating Fibrosis and Inflammation in PAH

Reata Pharmaceuticals, a clinical-stage biopharmaceutical company, recently presented results from the LARIAT trial investigating the drug bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). The study entitled “Bardoxolone Methyl Evaluation in Patients with Pulmonary Arterial Hypertension (PAH)” was presented in the 2015 American College…

Pulmonary Fibrosis Foundation Reveals Top Research Grant Winners for 2015

One of the country’s leading organizations dedicated to finding a cure for pulmonary fibrosis (PF), the Pulmonary Fibrosis Foundation (PFF), recently revealed the recipients of this year’s Established Investigator and Junior Investigator Awards. These prestigious research grants are directly supported by the Foundation’s Research Fund to Cure Pulmonary Fibrosis, and given only to…

In IPF Study, Fibroblasts Seen as More Aggressive with USP13 Loss

In a recent study entitled “Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis,” a team of researchers investigated the differences in gene expression in fibroblast foci in patients with idiopathic pulmonary fibrosis (IPF). They found that the expression of a particular gene, USP13,…

ProMetic’s PBI-4050 Receives Orphan Drug Designation by the European Commission for Idiopathic Pulmonary Fibrosis Treatment

ProMetic Life Sciences, Inc., a biopharmaceutical company focused on plasma-derived therapeutics and small-molecule drug development, recently announced that its product PBI-4050 for the treatment of idiopathic pulmonary fibrosis (IPF) has been granted orphan drug designation status by the European Commission. IPF is a progressive fatal lung disease of unknown…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums